Results 11 to 20 of about 37,314 (262)

Predictors and outcomes of heart failure with mid-range ejection fraction. [PDF]

Eur J Heart Fail, 2018
Aims While heart failure with preserved (HFpEF) and reduced ejection fraction (HFrEF) are well described, determinants and outcomes of heart failure with mid‐range ejection fraction (HFmrEF) remain unclear. We sought to examine clinical and biochemical predictors of incident HFmrEF in the community.
Bhambhani V, Kizer JR, Lima JAC, van der Harst P, Bahrami H, Nayor M, de Filippi CR, Enserro D, Blaha MJ, Cushman M, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Lee DS, Brouwers FP, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL, Levy D, Herrington DM, van Gilst WH, Bertoni AG, Larson MG, de Boer RA, Gottdiener JS, Shah SJ, Ho JE.   +36 more
europepmc   +8 more sources

Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction [PDF]

JACC: Heart Failure, 2017
In this study, the authors used biomarker profiles to characterize differences between patients with acute heart failure with a midrange ejection fraction (HFmrEF) and compare them with patients with a reduced (heart failure with a reduced ejection fraction [HFrEF]) and preserved (heart failure with a preserved ejection fraction [HFpEF]) ejection ...
Tromp, Jasper, Khan, Mohsin A. F., Mentz, Robert J., O'Connor, Christopher M., Metra, Marco, Dittrich, Howard C., Ponikowski, Piotr, Teerlink, John R., Cotter, Gad, Davison, Beth, Cleland, John G. F., Givertz, Michael M., Bloomfield, Daniel M., Van Veldhuisen, Dirk J., Hillege, Hans L., Voors, Adriaan A., van der Meer, Peter   +16 more
core   +19 more sources

Heart failure with mid-range or mildly reduced ejection fraction [PDF]

Nature Reviews Cardiology, 2021
Left ventricular ejection fraction (EF) remains the major parameter for diagnosis, phenotyping, prognosis and treatment decisions in heart failure. The 2016 ESC heart failure guidelines introduced a third EF category for an EF of 40-49%, defined as heart failure with mid-range EF (HFmrEF).
Gianluigi Savarese, Davide Stolfo, Gianfranco Sinagra, Lars H. Lund   +3 more
openaire   +5 more sources

Mortality from Heart Failure with Mid-Range Ejection Fraction. [PDF]

Arq Bras Cardiol, 2022
The prognostic importance of the classification 'heart failure (HF) with mid-range ejection fraction (EF)' remains uncertain.To analyze the clinical characteristics, comorbidities, complications, and in-hospital and late mortality of patients classified as having HF with mid-range EF (HFmrEF - EF: 40%-49%), and to compare them to those of patients with
Dutra GP, Gomes BFO, Carmo Júnior PRD, Petriz JLF, Nascimento EM, Pereira BB, Oliveira GMM.   +6 more
europepmc   +3 more sources

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction [PDF]

ESC Heart Failure, 2020
Aims Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients ...
Nobuyuki Enzan, Shouji Matsushima, Tomomi Ide, Hidetaka Kaku, Taiki Higo, Miyuki Tsuchihashi‐Makaya, Hiroyuki Tsutsui   +6 more
doaj   +2 more sources

Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. [PDF]

European Journal of Heart Failure, 2018
AIMS: We tested the hypothesis that candesartan improves outcomes in heart failure (HF) with mid-range ejection fraction [HFmrEF; ejection fraction (EF) 40-49%].
Borlaug, Chioncel, Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration, Fonarow, Koh, Lam, Lam, Lang, Lofman, Lupon, Mele, Meta-analysis Global Group in Chronic Heart Failure (MAGGIC), Nauta, Paulus, Pfeffer, Ponikowski, Rastogi, Rickenbacher, Sartipy, Solomon, Solomon, Solomon, Swedberg, Tsuji, Vedin, Yusuf   +25 more
core   +4 more sources

Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. [PDF]

Eur Heart J, 2020
Abstract Secondary mitral regurgitation and secondary tricuspid regurgitation due to heart failure (HF) remain challenging in almost every aspect: increasing prevalence, poor prognosis, notoriously elusive in diagnosis, and complexity of therapeutic management.
Bartko PE, Hülsmann M, Hung J, Pavo N, Levine RA, Pibarot P, Vahanian A, Stone GW, Goliasch G.   +8 more
europepmc   +5 more sources

Heart Failure with Mid-range Ejection Fraction: Lessons from CHARM. [PDF]

Card Fail Rev, 2018
The newly defined category of heart failure (HF) with mid-range ejection fraction (HFmrEF; EF 40–49 %) is beginning to be characterised but little is known about the potential for treating it. Trials and observational studies suggest that standard therapy for HF with reduced ejection fraction (HFrEF; EF <40 %) may also offer some benefit to patients
Lund LH.
europepmc   +3 more sources

Heart failure with mid-range ejection fraction. Where are we today? [PDF]

Българска кардиология, 2021
Bulgarian Society of Cardiology adhere to the European Guidelines on Heart Failure (HF). The fi nalized studies and many debates and analyses after 2016 are prerequisite to creation of a new guideline for diagnosis and management on these patients.
Tzvetana Katova
doaj   +5 more sources

Heart failure with mid-range ejection fraction: Current evidence and uncertainties

Monaldi Archives for Chest Disease, 2019
Heart failure (HF) with mid-range ejection fraction (HFmrEF) has been conceptualized by the European Society of Cardiology guidelines with the aim of stimulating research to fill a gap in knowledge: whether such a condition exists as a distinct ...
Raffaele Martone, Niccolò Marchionni, Francesco Cappelli   +2 more
doaj   +5 more sources